Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
TheFly reported on June 3 that BofA Securities analyst Jason Zemansky increased the price target on RCKT to $10 from $9 while maintaining a Buy rating on the shares.








